ClinicalImpact™ Melanoma: Expert Guidance and Resources to Optimize Care Along the Treatment Continuum

Download All
This comprehensive program gathers expert insights into best practice management of patients with melanoma, featuring expert-authored commentaries on timely topics in melanoma, a series of focused MedicalMinute™ videos to fit your busy schedule, and downloadable slides from a live Webinar.
person default
Allison Betof Warner, MD, PhD
Trish Brothers, BSN
Michael A. Davies, MD, PhD
Douglas B. Johnson, MD, MSCI
Evan J. Lipson, MD
person default
Megan Schollenberger, MSN, CRNP
Ahmad Tarhini, MD, PhD

Downloadable Slidesets

Download this slideset to gain key insights on adjuvant therapy and best practice management of high-risk melanoma through the use of targeted therapy and immunotherapy

Ahmad Tarhini, MD, PhD Released: November 3, 2020

Download this slideset to gain key insights into current therapeutic strategies in advanced melanoma, including optimal approaches for managing CNS metastases.

Michael A. Davies, MD, PhD Released: November 3, 2020

Download this short summary slideset of key takeaways from a live CCO Webinar focused on current management of patients with high-risk resectable or metastatic melanoma.

Michael A. Davies, MD, PhD Ahmad Tarhini, MD, PhD Released: November 6, 2020

ClinicalThought

How do you choose among approved adjuvant therapies for BRAF V600E/K high-risk melanoma? Read my thoughts on factors to consider when selecting adjuvant targeted therapy for your patients.

Douglas B. Johnson, MD, MSCI Released: October 19, 2020

Here are my thoughts on key considerations when selecting frontline therapy for patients with metastatic melanoma, including when targeted therapy may be preferred over immunotherapy, factors that affect the selection of single-agent or combination immunotherapy, and when to discontinue immunotherapy.

person default Allison Betof Warner, MD, PhD Released: February 17, 2021

Experts answer frequently asked questions on the management of melanoma, including adjuvant therapy selection, considerations for frontline treatment, and biomarker testing.

Michael A. Davies, MD, PhD Ahmad Tarhini, MD, PhD Released: March 3, 2021

MedicalMinutes

In this engaging and concise interactive module, gain insights on empowering patients with melanoma to be a central figure in their own care before, during, and after treatment.

Trish Brothers, BSN Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 2, 2021 Expired: March 1, 2022

In this engaging and concise interactive virtual presentation, learn how melanoma experts utilize biomarkers such as BRAF, NRAS, c-KIT, and PD-L1, to inform treatment decisions.

Evan J. Lipson, MD person default Megan Schollenberger, MSN, CRNP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 12, 2021 Expired: March 11, 2022

In this concise interactive module, learn from experts about emerging therapeutic regimens for advanced melanoma, including tumor-infiltrating lymphocytes, intratumorally administered agents, and targeted therapy combinations.

Evan J. Lipson, MD person default Megan Schollenberger, MSN, CRNP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 19, 2021 Expired: March 18, 2022

In this concise interactive module, learn how melanoma experts apply current treatment algorithms in multiple settings, including adjuvant therapy and unresectable or metastatic disease.

Evan J. Lipson, MD person default Megan Schollenberger, MSN, CRNP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 26, 2021 Expired: March 25, 2022
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Bristol-Myers Squibb
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue